TDC
INM icon

Thompson Davis & Co’s InMed Pharmaceuticals INM Stock Holding History

Thompson Davis & Co’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,249
Closed -$22.4K – 171
2025
Q3 		$22.4K Buy
+10,249
New +$24.7K 0.01% 145

Other funds holding INM

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Thompson Davis & Co's INM Position: Q4 2025 in Review

Thompson Davis & Co sold out of InMed Pharmaceuticals (INM) in Q4 2025, closing a stake of 10,249 shares — an estimated $22.4K sold.

Thompson Davis & Co first reported a position in INM in Q3 2025 and held it in 1 quarter. The position peaked at $22.4K in Q3 2025. 7 funds tracked by Wall St. Rank hold INM as of Q4 2025.

  • Thompson Davis & Co reported no remaining InMed Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Thompson Davis & Co sold 10,249 InMed Pharmaceuticals shares in Q4 2025, an estimated $22.4K.
  • Thompson Davis & Co first reported a position in InMed Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Thompson Davis & Co's InMed Pharmaceuticals position peaked at $22.4K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q4 2025.

Based on Thompson Davis & Co's 13F filing for Q4 2025, filed 12 Jan 2026.